Experienced in Malignant Mixed Mullerian Tumor

Dr. Elber S. Camacho

Hematology Oncology
1180 N Indian Canyon Dr, Ste E218, 
Palm Springs, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Malignant Mixed Mullerian Tumor
1180 N Indian Canyon Dr, Ste E218, 
Palm Springs, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elber Camacho is a Hematologist Oncology provider in Palm Springs, California. Dr. Camacho is rated as an Experienced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Breast Cancer, Essential Thrombocythemia, Paget Disease of the Breast, and Hodgkin Lymphoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

1180 N Indian Canyon Dr, Ste E218, Palm Springs, CA 92262

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
Enrollment Status: Completed
Publish Date: July 03, 2023
View 7 Less Clinical Trials

3 Total Publications

An unusual case of primary acinar cell carcinoma of the liver and its treatment.
An unusual case of primary acinar cell carcinoma of the liver and its treatment.
Journal: Journal of gastrointestinal oncology
Published: October 12, 2019
Similar Doctors
Advanced in Malignant Mixed Mullerian Tumor
Dr. Kishore Sehgal
Hematology Oncology | Hematology | Oncology
Advanced in Malignant Mixed Mullerian Tumor
Dr. Kishore Sehgal
Hematology Oncology | Hematology | Oncology

Hematology-Oncology Consultants

301 N San Jacinto St, 
Hemet, CA 
 (24.5 miles away)
951-717-8707
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kishore Sehgal is a Hematologist Oncology specialist and a Hematologist in Hemet, California. Dr. Sehgal is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration.

Advanced in Malignant Mixed Mullerian Tumor
Dr. Siamak Saadat
Hematology Oncology | Oncology | Hematology
Advanced in Malignant Mixed Mullerian Tumor
Dr. Siamak Saadat
Hematology Oncology | Oncology | Hematology

City Of Hope Medical Foundation

6939 Palm Ct, 
Riverside, CA 
 (49.7 miles away)
951-683-6771
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Siamak Saadat is a Hematologist Oncology specialist and an Oncologist in Riverside, California. Dr. Saadat has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Familial Colorectal Cancer, and Inflammatory Breast Cancer.

Advanced in Malignant Mixed Mullerian Tumor
Dr. Natasha Garg
Hematology Oncology | Oncology
Advanced in Malignant Mixed Mullerian Tumor
Dr. Natasha Garg
Hematology Oncology | Oncology

City Of Hope Medical Foundation

6939 Palm Ct, 
Riverside, CA 
 (49.7 miles away)
951-683-6771
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Natasha Garg is a Hematologist Oncology specialist and an Oncologist in Riverside, California. Dr. Garg is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Camacho's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 81 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile